Products
Pre-made Envafolimab benchmark antibody ( Single Domain Variable Fragment;H, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-188
Pre-made Envafolimab benchmark antibody (Single Domain Variable Fragment;H, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Envafolimab is a novel, single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-188-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-188-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-188-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-188-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody |
| INN Name | Envafolimab |
| Target | CD274 |
| Format | Single Domain Variable Fragment;H |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | na |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Alphamab;3D Medicines;Sun Yat-Sen University |
| Conditions Approved | na |
| Conditions Active | Biliary cancer;Breast cancer;Solid tumours;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma |
| Conditions Discontinued | na |
| Development Tech | na |
<